Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: cordio s. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R, Petralia G, Restuccia N, Todaro AM, Serraino D, Giuffrida D, Cordio S, Giannitto-Giorgio C, Salice P, Ursino M, Novello G, Marletta F, Manusia M. Bordonaro R, et al. Among authors: cordio s. Leuk Lymphoma. 2004 Jan;45(1):93-100. doi: 10.1080/1042819031000139765. Leuk Lymphoma. 2004. PMID: 15061203 Clinical Trial.
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Reni M, et al. Among authors: cordio s. Lancet Oncol. 2005 Jun;6(6):369-76. doi: 10.1016/S1470-2045(05)70175-3. Lancet Oncol. 2005. PMID: 15925814 Clinical Trial.
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale. Colucci G, et al. Among authors: cordio s. J Clin Oncol. 2005 Aug 1;23(22):4866-75. doi: 10.1200/JCO.2005.07.113. Epub 2005 Jun 6. J Clin Oncol. 2005. PMID: 15939922 Clinical Trial.
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA. Reni M, et al. Among authors: cordio s. Br J Cancer. 2006 Mar 27;94(6):785-91. doi: 10.1038/sj.bjc.6603026. Br J Cancer. 2006. PMID: 16508631 Free PMC article. Clinical Trial.
61 results